Dr Spencer Collis

Clinical Medicine, School of Medicine and Population Health

Reader in Genome Stability

Head of the Genome Stability Group

s.collis@sheffield.ac.uk
+44 114 215 9043

The Medical School

Full contact details

Dr Spencer Collis
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

1994 - 1997
BSc (Hons): Biochemistry, UMIST

1997 - 2000
PhD: Oncology, CRUK Paterson Institute for Cancer Research

2001 - 2004
Post-Doc: Prof. Theodore DeWeese laboratory, Johns Hopkins University

2004 - 2009
Post-Doc: Dr Simon Boulton laboratory, Clare Hall Laboratories, CRUK London Research Institute

2009 - 2013
Group leader: Institute for Cancer Studies, University of Sheffield

2013 - 2015
Senior Lecturer: Academic unit of Molecular Oncology, Department of Oncology, University of Sheffield

2016 -
Reader: Academic unit of Molecular Oncology, Department of Oncology, University of Sheffield

Current PhD Opportunities:

Deconvoluting the spatial multi-omic landscape of high-grade glioma to target post-surgical residual disease

Research interests

The overarching research goals of the Collis laboratory is to identify and functionally characterise novel factors that are important for the maintenance of genome integrity in human cells. This research also aims to establish if such factors are novel drug targets and/or biomarkers that can be exploited to improve the treatment of diseases such as cancer, either alone, or in combination with existing chemo- and/or radio-therapeutic regimes. To achieve this, the Collis group collaborate with a range of national and international scientists and clinicians to maximise the potential therapeutic impact of their basic biological discoveries.

Funding Sources

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Jones CG, Vanderlinden A, Rominiyi O & Collis SJ (2024) Development and optimisation of Tumour Treating Fields (TTFields) delivery within 3D primary glioma stem cell-like models of spatial heterogeneity. Cancers, 16(5). View this article in WRRO
Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al (2024) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12.
Vanderlinden A, Jones CG, Myers KN, Rominiyi O & Collis SJ (2023) DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer.
Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
Rominiyi O & Collis SJ (2022) DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.. Molecular Oncology, 16(1), 11-41. View this article in WRRO
Carmell N, Rominiyi O, Myers KN, McGarrity-Cottrell C, Vanderlinden A, Lad N, Perroux-David E, El-Khamisy SF, Fernando M, Finegan KG , Brown S et al (2021) Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13(5). View this article in WRRO
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions.. Br J Cancer, 124(4), 697-709.
Bennett LG, Wilkie AM, Antonopoulou E, Ceppi I, Sanchez A, Vernon EG, Gamble A, Myers KN, Collis SJ, Cejka P & Staples CJ (2020) MRNIP is a replication fork protection factor.. Sci Adv, 6(28), eaba5974.
Rominiyi O, Al-Tamimi Y & Collis SJ (2019) The 'Ins and Outs' of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?. Cancers (Basel), 11(3).
Barone G, Arora A, Ganesh A, Abdel-Fatah T, Moseley P, Ali R, Chan SY, Savva C, Schiavone K, Carmell N , Myers KN et al (2018) The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.. Oncotarget, 9(50), 29508-29524.
Myers KN, Barone G, Ganesh A, Staples CJ, Howard AE, Beveridge RD, Maslen S, Skehel JM & Collis SJ (2016) The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability.. Sci Rep, 6, 35548.
Barone G, Staples CJ, Ganesh A, Patterson KW, Bryne DP, Myers KN, Patil AA, Eyers CE, Maslen S, Skehel JM , Eyers PA et al (2016) Human CDK18 promotes replication stress signaling and genome stability.. Nucleic Acids Res, 44(18), 8772-8785.
Staples CJ, Barone G, Myers KN, Ganesh A, Gibbs-Seymour I, Patil AA, Beveridge RD, Daye C, Beniston R, Maslen S , Ahel I et al (2016) MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.. Cell Rep, 16(10), 2565-2575.
Johnson CA & Collis SJ (2016) Ciliogenesis and the DNA damage response: a stressful relationship.. Cilia, 5, 19.
Beveridge RD, Staples CJ, Patil AA, Myers KN, Maslen S, Skehel JM, Boulton SJ & Collis SJ (2014) The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.. Cell Cycle, 13(21), 3450-3459.
Patil AA, Sayal P, Depondt M-L, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M , Carroll TA et al (2014) FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.. Oncotarget, 5(15), 6414-6424.
Staples CJ, Myers KN, Beveridge RDD, Patil AA, Howard AE, Barone G, Lee AJX, Swanton C, Howell M, Maslen S , Skehel JM et al (2014) Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability.. J Cell Sci, 127(Pt 13), 2910-2919.
Staples CJ, Myers KN, Beveridge RDD, Patil AA, Lee AJX, Swanton C, Howell M, Boulton SJ & Collis SJ (2012) The centriolar satellite protein Cep131 is important for genome stability.. J Cell Sci, 125(Pt 20), 4770-4779.
Rominiyi O, McGarrity-Cottrell C, Myers KN, Jones CG, Wosnitzka K, Williams ST, Vanderlinden A, Antohi A-G, Gomez-Roman N, Chalmers AJ , Sinha S et al () Ex-vivo models of post-surgical residual disease in human glioblastoma. F1000Research, 13, 1316-1316.

All publications

Journal articles

Lad N, Jones CG, Myers KN, McGarrity-Cottrell CL, Finegan KG, Rominiyi O & Collis SJ (2024) DNAR-05. VALIDATING THE ERK5 PROTAC OS11 AS A POTENTIAL NOVEL THERAPEUTIC INEX VIVO GLIOMA STEM CELL MODELS OF INTRATUMOURAL HETEROGENEITY AND RESIDUAL DISEASE. Neuro-Oncology, 26(Supplement_8), viii118-viii118.
Jones CG, Vanderlinden A, Rominiyi O & Collis SJ (2024) Development and optimisation of Tumour Treating Fields (TTFields) delivery within 3D primary glioma stem cell-like models of spatial heterogeneity. Cancers, 16(5). View this article in WRRO
Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al (2024) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12.
Derby S, Dutton L, Strathdee KE, Stevenson K, Koessinger A, Jackson M, Tian Y, Yu W, Mclay K, Misquitta J , Alsharif S et al (2023) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, noad210.
Vanderlinden A, Jones CG, Myers KN, Rominiyi O & Collis SJ (2023) DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer.
McGarrity-Cottrell C, Myers K, Dunning M, Bagga V, Sinna S, Al-Tamimi Y, Rominiyi O & Collis S (2023) DEfiNING SPATIAL HETEROGENEITY OF A NOVEL LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO DEVELOP STRATEGIES FOR TARGETED THERAPY. Neuro-Oncology, 25(Supplement_3), iii14-iii14.
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S , Kennerley AJ et al (2023) Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116. View this article in WRRO
McGarrity - Cottrell C, Myers K, Wang D, Dunning M, Bagga V, Al-Tamimi Y, Sinha S, Rominiyi O & Collis S (2022) STEM-02. GENERATION AND CHARACTERISATION OF A LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO IDENTIFY NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 24(Supplement_7), vii31-vii31.
Vanderlinden A, Rominiyi O, Collis S, Jones C, Myers K & McGarrity - Cottrell C (2022) DNAR-12. COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS. Neuro-Oncology, 24(Supplement_7), vii93-vii93.
Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
Rominiyi O & Collis SJ (2022) DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.. Molecular Oncology, 16(1), 11-41. View this article in WRRO
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions (vol 124, pg 697, 2020). BRITISH JOURNAL OF CANCER, 125(4), 623-623.
Rominiyi O, Vanderlinden A, Myers K, Gomez-Roman N, Dar D, Bagga V, Jellinek DA, Chalmers AJ, Carroll TA, Al-Tamimi Y & Collis SJ (2021) O2: TOWARDS A LIVING BIOBANK OF SURGICALLY-RELEVANT 3-DIMENSIONAL GLIOBLASTOMA STEM CELL MODELS TO EVALUATE NOVEL THERAPEUTICS AND INTERROGATE INTRATUMOURAL HETEROGENEITY. British Journal of Surgery, 108(Supplement_1).
Carmell N, Rominiyi O, Myers KN, McGarrity-Cottrell C, Vanderlinden A, Lad N, Perroux-David E, El-Khamisy SF, Fernando M, Finegan KG , Brown S et al (2021) Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13(5). View this article in WRRO
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions.. Br J Cancer, 124(4), 697-709.
Bennett LG, Wilkie AM, Antonopoulou E, Ceppi I, Sanchez A, Vernon EG, Gamble A, Myers KN, Collis SJ, Cejka P & Staples CJ (2020) MRNIP is a replication fork protection factor.. Sci Adv, 6(28), eaba5974.
O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA , Choi J et al (2020) EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.. J Cell Sci, 133(9).
Rominiyi O, Myers K, Gomez-Roman N, Lad N, Dar D, Jellinek D, Chalmers A, Carroll T, Chen B, Al-Tamimi Y & Collis S (2019) RDNA-12. THE FANCONI ANAEMIA (FA) PATHWAY AND GLIOBLASTOMA: A NEW FOUNDATION FOR DNA DAMAGE RESPONSE TARGETED COMBINATIONS. Neuro-Oncology, 21(Supplement_6), vi209-vi209.
Rominiyi O, Myers K, Vanderlinden A, Dar D, Bagga V, Gomez-Roman N, Jellinek D, Carroll T, Chalmers A, Al-Tamimi Y & Collis S (2019) TMOD-39. EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA. Neuro-Oncology, 21(Supplement_6), vi271-vi271.
Rominiyi O, Al-Tamimi Y & Collis SJ (2019) The 'Ins and Outs' of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?. Cancers (Basel), 11(3).
Carmell N, Brown S, Khamisy S & Collis S (2018) NOVEL DRUG TARGETS TO AUGMENT TEMOZOLOMIDE SENSITIVITY IN HIGH-GRADE BRAIN TUMOURS. NEURO-ONCOLOGY, 20, 346-346.
Rominiyi O, Gomez-Roman N, Lad N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis SJ (2018) P04.74 Preclinical evaluation of combinations targeting the DNA damage response in 2D and 3D models of glioblastoma stem cells. Neuro-Oncology, 20(suppl_3), iii297-iii297.
Barone G, Arora A, Ganesh A, Abdel-Fatah T, Moseley P, Ali R, Chan SY, Savva C, Schiavone K, Carmell N , Myers KN et al (2018) The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.. Oncotarget, 9(50), 29508-29524.
Myers KN, Barone G, Ganesh A, Staples CJ, Howard AE, Beveridge RD, Maslen S, Skehel JM & Collis SJ (2016) The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability.. Sci Rep, 6, 35548.
Barone G, Staples CJ, Ganesh A, Patterson KW, Bryne DP, Myers KN, Patil AA, Eyers CE, Maslen S, Skehel JM , Eyers PA et al (2016) Human CDK18 promotes replication stress signaling and genome stability.. Nucleic Acids Res, 44(18), 8772-8785.
Staples CJ, Barone G, Myers KN, Ganesh A, Gibbs-Seymour I, Patil AA, Beveridge RD, Daye C, Beniston R, Maslen S , Ahel I et al (2016) MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.. Cell Rep, 16(10), 2565-2575.
Johnson CA & Collis SJ (2016) Ciliogenesis and the DNA damage response: a stressful relationship.. Cilia, 5, 19.
Patil AA, Hua P, Sellwood MA, Jellinek DA, Carroll TA, Chen B & Collis SJ (2015) OP21IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. Neuro-Oncology, 17(suppl 8), viii20.1-viii20.
Beveridge RD, Staples CJ, Patil AA, Myers KN, Maslen S, Skehel JM, Boulton SJ & Collis SJ (2014) The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.. Cell Cycle, 13(21), 3450-3459.
Patil AA, Sayal P, Depondt M-L, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M , Carroll TA et al (2014) FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.. Oncotarget, 5(15), 6414-6424.
Staples CJ, Myers KN, Beveridge RDD, Patil AA, Howard AE, Barone G, Lee AJX, Swanton C, Howell M, Maslen S , Skehel JM et al (2014) Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability.. J Cell Sci, 127(Pt 13), 2910-2919.
Staples CJ, Myers KN, Beveridge RDD, Patil AA, Lee AJX, Swanton C, Howell M, Boulton SJ & Collis SJ (2013) The centriolar satellite protein Cep131 is important for genome stability. Development, 140(2), e207-e207.
Staples CJ, Myers KN, Beveridge RDD, Patil AA, Lee AJX, Swanton C, Howell M, Boulton SJ & Collis SJ (2012) The centriolar satellite protein Cep131 is important for genome stability.. J Cell Sci, 125(Pt 20), 4770-4779.
Horejsí Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, Skehel JM, de Lange T & Boulton SJ (2010) CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.. Mol Cell, 39(6), 839-850.
Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, Martinez-Perez E, Boulton SJ & La Volpe A (2010) Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.. Mol Cell, 39(1), 25-35.
Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MSQ, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L , Lin J et al (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.. PLoS One, 5(6), e11208.
Collis SJ & Boulton SJ (2010) FANCM: fork pause, rewind and play.. EMBO J, 29(4), 703-705.
Horejŝí Z, Collis SJ & Boulton SJ (2009) FANCM-FAAP24 and HCLK2: roles in ATR signalling and the Fanconi anemia pathway.. Cell Cycle, 8(8), 1133-1137.
Youds JL, Barber LJ, Ward JD, Collis SJ, O'Neil NJ, Boulton SJ & Rose AM (2008) DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair.. Mol Cell Biol, 28(5), 1470-1479.
Collis SJ, Ciccia A, Deans AJ, Horejsí Z, Martin JS, Maslen SL, Skehel JM, Elledge SJ, West SC & Boulton SJ (2008) FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex.. Mol Cell, 32(3), 313-324.
Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, Petalcorin MIR, Martin JS, Collis SJ, Cantor SB, Auclair M , Tissenbaum H et al (2008) RTEL1 maintains genomic stability by suppressing homologous recombination.. Cell, 135(2), 261-271.
Marples B & Collis SJ (2008) Low-dose hyper-radiosensitivity: past, present, and future.. Int J Radiat Oncol Biol Phys, 70(5), 1310-1318.
Krueger SA, Collis SJ, Joiner MC, Wilson GD & Marples B (2007) Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity.. Int J Radiat Oncol Biol Phys, 69(4), 1262-1271.
Collis SJ & Boulton SJ (2007) Emerging links between the biological clock and the DNA damage response.. Chromosoma, 116(4), 331-339.
Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD & Boulton SJ (2007) HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.. Nat Cell Biol, 9(4), 391-401.
Qian DZ, Kachhap SK, Collis SJ, Verheul HMW, Carducci MA, Atadja P & Pili R (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. CANCER RES, 66(17), 8814-8821.
Collis SJ, Barber LJ, Ward JD, Martin JS & Boulton SJ (2006) C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair.. DNA Repair (Amst), 5(11), 1398-1406.
Collis SJ, DeWeese TL, Jeggo PA & Parker AR (2005) The life and death of DNA-PK.. Oncogene, 24(6), 949-961.
Collis SJ, Schwaninger JM, Ntambi AJ, Keller TW, Nelson WG, Dillehay LE & Deweese TL (2004) Evasion of early cellular response mechanisms following low level radiation-induced DNA damage.. J Biol Chem, 279(48), 49624-49632.
Collis SJ & DeWeese TL (2004) Enhanced radiation response through directed molecular targeting approaches.. Cancer Metastasis Rev, 23(3-4), 277-292.
Collis SJ, Neutzel S, Thompson TL, Swartz MJ, Dillehay LE, Collector MI, Sharkis SJ & DeWeese TL (2004) Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates.. Radiat Res, 162(1), 48-55.
Marples B, Wouters BG, Collis SJ, Chalmers AJ & Joiner MC (2004) Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells.. Radiat Res, 161(3), 247-255.
Collis SJ, Khater K & DeWeese TL (2003) Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.. World J Urol, 21(4), 275-289.
Collis SJ, Swartz MJ, Nelson WG & DeWeese TL (2003) Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.. Cancer Res, 63(7), 1550-1554.
Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM & Deweese TL (2003) Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.. Int J Radiat Biol, 79(1), 53-60.
Collis SJ, Sangar VK, Tighe A, Roberts SA, Clarke NW, Hendry JH & Margison GP (2002) Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells.. Nucleic Acids Res, 30(2), E1.
Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH & Margison GP (2001) Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.. Nucleic Acids Res, 29(7), 1534-1538.
Rominiyi O, McGarrity-Cottrell C, Myers KN, Jones CG, Wosnitzka K, Williams ST, Vanderlinden A, Antohi A-G, Gomez-Roman N, Chalmers AJ , Sinha S et al () Ex-vivo models of post-surgical residual disease in human glioblastoma. F1000Research, 13, 1316-1316.
Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al () Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12, 954-954.

Chapters

Marples B, Krueger SA, Collis SJ & Joiner MC (2008) Low dose hyper-radiosensitivity: A historical perspective, Targeted Radionuclide Tumor Therapy: Biological Aspects (pp. 329-347).
Collis SJ (2007) Molecular targeting of DNA repair: A means to improve therapeutic index, New Research on DNA Repair (pp. 1-37).

Conference proceedings papers

Gagg H, Williams S, Rominiyi O, Danson S, Collis S & Wells G (2023) DEVELOPMENT OF GLIEXP; A HIGH-THROUGHPUT EX VIVO DRUG SCREENING PLATFORM FOR GLIOBLASTOMA. Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) F-1286: Ex vivo-led drug discovery in glioblastoma. Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022. View this article in WRRO
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis S (2022) Tumour treating fields (TTFields) therapy for glioblastoma: a quantitative and qualitative summary of research and advances in our understanding. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Zizzo C, Keating J, Sinha S, Al-Tamimi Y, Dyson B, Collis S & Rominiyi O (2022) Patient-centric design of a neuro-oncology research primer to enhance communication and support of specimen donation for preclinical research. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Cottrell CM, Myers K, Dunning M, Bagga V, Sinha S, Al-Tamimi Y, Wang D, Rominiyi O & Collis S (2022) Development of unique ex vivo models of post-surgical residual glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Rominiyi O, Myers K, Gomez-Roman N, Jellinek DA, Chalmers AJ, Carroll TA, Chen B, Al-Tamimi Y & Collis S (2022) Combined inhibition of the Fanconi anaemia (FA) pathway and ATR promotes R-loop generation and profound radiosensitisation in glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Vanderlinden A, McGarrity-Cottrell C, Myers K, Carroll TA, Al-Tamimi Y, Rominiyi O & Collis S (2022) DNA damage response inhibitor combinations to enhance TTFields potency using clinically relevant ex-vivo glioblastoma models. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Rominiyi O, Gomez-Roman N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis S (2018) FA-BASED COMBINATIONS TO TARGET THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 20 (pp 358-358)
Rominiyi O, Gomez-Roman N, Lad N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis SJ (2018) PRECLINICAL EVALUATION OF COMBINATIONS TARGETING THE DNA DAMAGE RESPONSE IN 2D AND 3D MODELS OF GLIOBLASTOMA STEM CELLS. NEURO-ONCOLOGY, Vol. 20 (pp 297-297)
Marples B, Krueger SA, Wilson TG, Dabjan MB, Lee KC, Hymas RV, Wilson GD & Collis SJ (2016) Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 96(2) (pp E566-E567). Boston, Massachusetts, USA View this article in WRRO
Patil AA, Hua P, Sellwood MA, Jellinek DA, Carroll TA, Chen B & Collis SJ (2015) IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. NEURO-ONCOLOGY, Vol. 17 (pp 20-20)
DeWeese TL, Collis SJ, Lupold SE, Chowdury W, Kudrolli T, Swartz M & Rodriguez R (2007) Optimization of siRNA-transgene expression in adenoviral vector systems for radiation sensitizing strategies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 69(3) (pp S595-S596)
Collis SJ, Barber LJ, Martin JS, Ward JD & Boulton SJ (2006) HCLK2 couples FANCD2 to stalled replication forks and functions in the mammalian S-phase checkpoint. BREAST CANCER RESEARCH, Vol. 8 (pp S6-S6)

Preprints

Derby S, Dutton L, Strathdee K, Stevenson K, Clough E, Koessinger A, Yu W, Tian Y, Gilmour L, McGhee E , McGarrity-Cottrell C et al (2023) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis, Research Square Platform LLC.
Birch J, Strathdee K, Stevenson K, Derby S, Dutton L, Clough E, Koessinger A, Gilmour L, McGhee E, McGarrity-Cottrell C , Dibekeme AA et al (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM, Research Square Platform LLC.
O’Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA , Choi J et al (2019) EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer, Cold Spring Harbor Laboratory.
O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis S, Fennell D , Choi J et al () EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer.

Research group

Research Group

Dr. Katie Myers (Research Assistant/Lab Manager)
Dr. Callum Jones (Postdoctoral Research Associate)
Dr. Nikita Lad (Postdoctoral Research Associate)
Dr. Sophie Williams (Clinical PhD Fellow)
Connor McGarrity-Cottrell (PhD student)
Hannah Gagg (PhD student with Dr. Greg Wells and Mr. Ola Rominiyi)
Kelsey Wosnitzka (PhD student with Mr. Ola Rominiyi)
Rebecca Livesey (PhD student with Prof. Fred Claeyssens)
Tegan Torpey (PhD student with Mr. Ola Rominiyi and Prof. Fred Claeyssens)

Teaching interests: M.Sc. Molecular Medicine
M.Sc. Translational Oncology
MSc Genomic Medicine